CoChat
Sign Up
Cited by 53Nanoparticle-Based Drug DeliveryBarrier Structure and Function StudiesAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems

Open access
Grabrucker, Andreas M., Chhabra, Resham, Belletti, Daniela, Forni, Flavio, Vandelli, Maria Angela, Ruozi, Barbara, Tosi, Giovanni·2013·Topics in Medicinal Chemistry
DOI 10.1007/7355_2013_22
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1007/7355_2013_22

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Due to high electrical resistance and tight junctions between endothelial cells caused by encapsulation by pericytes and astrocytes, only water and other small molecules can penetrate without restrictions by passive transcellular diffusion through the BBB.

    “Due to the presence of high electrical resistance and tight junctions between endothelial cells caused by their encapsulation by the pericytes and astrocytes, only water and other small molecules can penetrate without restrictions by passive transcellular diffusion through the BBB [189,192].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [192]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 92

  1. Pardridge WM (2003) Blood brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90–105 · DOI · Paper page
  2. Burke M, Langer R, Brim H (1999) Central nervous system: drug delivery to treat. Wiley, New York
  3. Ambikanandan M, Ganesh S, Aliasgar S (2003) Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 6(2):252–273
  4. Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR (1988) Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 245(3):816–822
  5. Begley DJ, Sqiires LK, Zlokovic BV et al (1990) Permeability of the blood–brain barrier to the immunosuppresive cyclic peptide cyclosporin A. J Neurochem 55:1222–1230 · DOI
  6. Tsuji A, Tamai I (1997) Blood–brain barrier function of P-glycoprotein. Adv Drug Del Rev 25(2):287–298 · DOI
  7. Cordon-Cardo C, O’Brien JP, Casals D et al (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 86:695–698 · DOI
  8. Borst P, Evers R, Kool M et al (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302 · DOI · Paper page
  9. Sun H, Dai H, Shaik N et al (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83–105 · DOI
  10. Saito Y, Wright EM (1983) Bicarbonate transport across the frog choroid plexus and its control by cyclic nucleotides. J Physiol 336:635–648 · DOI
  11. Yarchoan R, Broder S (1987) Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. N Engl J Med 316:557–564 · DOI
  12. Dykstra KH, Arya A, Arriola DM et al (1993) Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharmacol Exp Ther 267:1227–1236
  13. Mak M, Fung L, Strasser JF et al (1995) Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol 1995(26):91–102 · DOI
  14. Oldendorf WH (1972) Cerebrospinal fluid formation and circulation. Prog Nuc Med 1:336–358
  15. Davson H (1969) The cerebrospinal fluid. Handbook Neurochem 2:23–48 · DOI
  16. Lorenzo AV, Hedley-Whyte ET, Eisenberg JM et al (1975) Increased penetration of horseradish peroxidase across the blood–brain barrier induced by Metrazol seizures. Brain Res 88:136–140 · DOI
  17. Neuwelt EA, Dahlborg SA (1989) Blood–brain barrier disruption in the treatment of brain tumors: clinical implications. In: Neuwelt EA (ed) Implications of the blood brain barrier and its manipulation: clinical aspects, vol 2. Plenum, New York, pp 195–262 · DOI
  18. Chio CC, Baba T, Black KL (1992) Selective blood–tumor pro-barrier disruption by leukotrienes. J Neurosurg 77:407–410 · DOI
  19. Bodor N, Buchwald P (1997) Drug targeting via retrometabolic approaches. Pharmacol Ther 76:1–27 · DOI
  20. Somogyi G, Nishitani S, Nomi D et al (1998) Targeted drug delivery to the brain via phosphonate derivatives. I: design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int J Pharm 166:15–26 · DOI
  21. Bahadur S, Pathak K (2012) Physicochemical and physiological considerations for efficient nose-to-brain targeting. Exp Opin Drug Del 9(1):19–31 · DOI
  22. Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47(1):49–54
  23. Harbaugh RE, Saunders RL, Reeder RF (1988) Use of implantable pumps for central nervous system drug infu- sions to treat neurological disease. Neurosurgery 23(6):693–698 · DOI
  24. Bartneck M, Keul HA, Zwadlo-Klarwasser G et al (2010) Phagocytosis independent extracellular nanoparticles clearance by human immune cells. Nano Lett 10:59–63 · DOI
  25. Chonn A, Cullis PR, Devine DV (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146:234–4241 · DOI
  26. Bertrand N, Leroux JC (2012) The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Rel 161(2):152–163 · DOI
  27. Tosi G, Costantino L, Ruozi B et al (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Exp Opin Drug Del 5:155–174 · DOI
  28. Shi N, Pardridge WM (2000) Noninvasive gene targeting to the brain. Prot Natl Acad Sci USA 97:7567–7572 · DOI
  29. Lockman PR, Mumper RJ, Khan MA et al (2002) Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm 28(1):1–13 · DOI · Paper page
  30. Alyautidin RN, Gother D, Petrov V (1995) Analgesic activity of the hexapeptide dalagrin adsorbed on the surface of polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Eur J Pharm Biopharm 41:44–48
  31. Kreuter J (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 4:484–488 · DOI
  32. Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131–139 · DOI
  33. Ji B, Maeda J, Higuchi M et al (2006) Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 78:851–855 · DOI
  34. Scherrmann JM, Temsamani J (2005) The use of Pep: trans vectors for the delivery of drugs into the central nervous system. Int Congr Ser 1277:199–211 · DOI
  35. Gabathuler R, Arthur G, Kennard M et al (2005) Development of a potential protein vector (NeuroTrans) to deliver drugs across the bloodbrain barrier. Int Congr Ser 1277:171–184 · DOI
  36. Chakraborty C, Sarkar B, Hsu CH et al (2009) Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol 93:285–286 · DOI
  37. Umezawa F, EtoY (1988) Liposomes targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Comm153:1038–1044 · DOI
  38. Wu D, Pardridge WM (1999) Blood–brain barrier transport of reduced folic acid. Pharm Res 16:415–419 · DOI
  39. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol Dis 37(1):48–57 · DOI
  40. Panyam J, Labhasetwar V (2004) Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 1:77–84 · DOI
  41. Dubowchik GM, Walker MA (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm Ther 83:67–123 · DOI
  42. Savic R, Luo L, Eisenberg A et al (2003) Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300:615–618 · DOI
  43. Cengelli F, Maysinger D, Tschudi-Monnet F et al (2006) Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharm Exp Therap 318:108–116 · DOI
  44. Tosi G, Ruozi B, Belletti D (2012) Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine (Lond) 7(8):1113–1116 · DOI
  45. Grislain L, Couvrer P, Lenaerts V (1983) Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 15:333–345 · DOI
  46. Tröster SD, Kreuter J (1988) Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly(methyl methacrylate) surfaces. Int J Pharm 45:91–100 · DOI
  47. Silva GA (2008) Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS. BMC Neurosci 9(Suppl 3):S4 · DOI
  48. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564–1569 · DOI
  49. Steiniger SC, Kreuter J, Khalansky AS et al (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759–767 · DOI
  50. Alyaudtin RN, Reichel A, Lobenberg R et al (2001) Interaction of poly(butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro. J Drug Target 9:209–221 · DOI
  51. Schroeder U, Sommerfeld P, Ulrich S et al (1998) Nanoparticle technology for delivery of drugs across the blood–brain barrier. J Pharm Sci 87:1305–1307 · DOI
  52. Zhang Y, Calon F, Zhu C et al (2003) Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 14:1–12 · DOI · Paper page
  53. Liu G, Men P, Peggy LR et al (2006) Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406(3):189–193 · DOI
  54. Weiss N, Miller F, Cazaubon S et al (2009) The blood–brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788(4):842–857 · DOI · Paper page
  55. Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13(23–24):1099–1106 · DOI
  56. Beduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947–4967 · DOI
  57. Koo YEL, Reddy GR, Bhojani M et al (2006) Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 85:1556–1577 · DOI
  58. Juillerat-Jeanneret L (2006) Critical analysis of cancer therapy using nanomaterials. In: Kumar CSSR (ed) Nanomaterials for cancer therapy and diagnosis. Wiley-VCH, Weinheim, pp 199–232
  59. Kreuter J, Alyautdin RN, Kharkevich DA et al (1995) Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171–174 · DOI
  60. Alyautdin RN, Tezikov EB, Ramge P et al (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15:67–74 · DOI
  61. Alyautdin RN, Petrov VE, Langer K et al (1997) Delivery of loperamide across the blood–brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325–328 · DOI
  62. Friese A, Seiller E, Quack G et al (2000) Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcya-noacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49:103–109 · DOI
  63. Kreuter J (1995) Nanoparticulate systems in drug delivery and targeting. J Drug Target 3:171–173 · DOI
  64. Aliautdin RN, Petrov VE, Ivanov AA et al (1996) Transport of the hexapeptide dalargin across the hematoencephalic barrier into the brain using polymer nanoparticles. Eksp Klin Farmakol 59:57–60
  65. Troster SD, Muller U, Kreuter J (1990) Modification of the body distribution of poly(methyl methyl methyl-acrylate) nanoparticles by coating with surfactants. Int J Pharm 61:85–100 · DOI
  66. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL (2011) Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci USA 108(46):18837–18842 · DOI
  67. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2(1):108–119 · DOI
  68. Emerich DF, Tracy MA, Ward KL et al (1999) Biocompatibility of poly (dl-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant 8:47–58 · DOI
  69. Menei P, Daniel V, Montero-Menei C et al (1993) Biodegradation and brain tissue reaction to poly(d, l-lactide-co-glycolide) microspheres. Biomaterials 14:470–478 · DOI
  70. Garcia-Garcia E, Andrieux K, Gil S et al (2007) Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298:274–923 · DOI
  71. Tosi G, Bortot B, Ruozi B et al (2013) Potential use of polymeric nanoparticles for drug delivery across the blood–brain barrier. Curr Med Chem 20(17):2212–2225 · DOI
  72. Li S (1999) Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 48:342–353 · DOI
  73. Costantino L, Gandolfi F, Tosi G et al (2005) Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier. J Control Rel 108:84–96 · DOI
  74. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F (2007) Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Rel 122:1–9 · DOI
  75. Vergoni AV, Tosi G, Tacchi R et al (2009) Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed Nanotechnol Biol Med 5:369–377 · DOI
  76. Tosi G, Fano RA, Bondioli L et al (2011) Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood–brain barrier. Nanomedicine 6(3):423–436 · DOI
  77. Grabrucker AM, Garner CC, Boeckers TM et al (2011) Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. PLoS One 6(3):e17851 · DOI
  78. Tosi G, Badiali L, Ruozi B et al (2012) Can Leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7(3):365–382 · DOI
  79. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164–14169 · DOI
  80. Zhang Y, Schlachetzki F, Pardridge WM (2003) Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11–18 · DOI
  81. Shi N, Zhang Y, Zhu C et al (2001) Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 98:12754–12759 · DOI
  82. Huwyler J, Yang J, Pardridge WM (1997) Targeted delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 282:1541–1546
  83. Qin J, Chen D, Hu H et al (2007) Body distribution of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi 127(9):1497–1501 · DOI
  84. Koziara JM, Lockman PR, Allen DD et al (2003) In situ blood–brain barrier transport of nanoparticles. Pharm Res 20:1772–1778 · DOI
  85. Xu G, Yong KT, Roy I et al (2008) Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood–brain barrier. Bioconjug Chem 19(6):1179–1185 · DOI
  86. Yim YS, Choi JS, Kim GT et al (2012) A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood–brain barrier (BBB). Chem Commun (Camb) 48(1):61–63 · DOI
  87. Barandeh F, Nguyen PL, Kumar R etal (2012) Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS One 7(1):e29424 · DOI
  88. Knezevic NZ, Slowing II, Lin VS-Y (2012) Tuning the release of anticancer drugs from magnetic iron oxide/mesoporous silica core/shell nanoparticles. ChemPlusChem 77:48–55 · DOI
  89. Gupta PK, Hung CT (1990) Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats. J Micro- encaps 7:85–94
  90. Pulfer SK, Gallo JM (1998) Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J. Drug Target 6:215–227 · DOI
  91. Xie Y, Wang Y, Zhang T et al (2012) Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors. J Biomed Sci 19:14 · DOI
  92. Grabrucker AM, Rowan M, Garner CC (2011) Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 1(1):13–23

Cited by

Sorted by citations

Metadata

Authors
Grabrucker, A. M., Chhabra, R., Belletti, D., Forni, F., Vandelli, M. A., Ruozi, B., & Tosi, G.
Affiliations
  • Universität Ulm (DE)
  • University of Modena and Reggio Emilia (IT)
Corresponding author
  • Grabrucker, Andreas M.
  • Tosi, Giovanni
ORCID
Venue
Topics in Medicinal Chemistry
Publisher
Springer Berlin Heidelberg
Published
2013
Pages
71-89
ISSN
  • 1862-2461 (ISSN-L)
  • 1862-247X
DOI
10.1007/7355_2013_22
OpenAlex
W87647640
Cited by
53
References
4
Citations by year
2026: 4 · 2025: 1 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 9 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 3 · 2014: 1
FWCI
1.52
Type
book chapter
Language
en
Open access
Licence
Locations
  • Topics in medicinal chemistry (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
blood-brain barrier, brain drug delivery, nanoparticles, biodegradable nanoparticles, targeted drug delivery, nano-bio interactions, neurological disorders, mental illness, anticancer agents, neuropeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review